Regeneron Pharmaceuticals, Inc.
REGN
$527.78
-$19.89-3.63%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.61B | 13.69B | 13.30B | 12.92B | 12.56B |
| Total Other Revenue | 480.00M | 515.00M | 548.10M | 572.20M | 537.00M |
| Total Revenue | 14.09B | 14.20B | 13.85B | 13.49B | 13.10B |
| Cost of Revenue | 7.21B | 7.10B | 6.82B | 6.57B | 6.38B |
| Gross Profit | 6.87B | 7.10B | 7.03B | 6.92B | 6.72B |
| SG&A Expenses | 2.90B | 2.95B | 2.90B | 2.83B | 2.72B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 14.60M | 14.60M | 14.10M | 13.60M | -1.60M |
| Total Operating Expenses | 10.13B | 10.07B | 9.73B | 9.41B | 9.10B |
| Operating Income | 3.96B | 4.13B | 4.11B | 4.08B | 4.00B |
| Income Before Tax | 4.98B | 4.78B | 4.97B | 4.59B | 4.04B |
| Income Tax Expenses | 484.90M | 367.30M | 314.90M | 265.50M | 184.20M |
| Earnings from Continuing Operations | 4.50K | 4.41K | 4.65K | 4.32K | 3.86K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.50B | 4.41B | 4.65B | 4.32B | 3.86B |
| EBIT | 3.96B | 4.13B | 4.11B | 4.08B | 4.00B |
| EBITDA | 4.46B | 4.61B | 4.58B | 4.53B | 4.44B |
| EPS Basic | 41.76 | 40.88 | 43.23 | 40.31 | 36.11 |
| Normalized Basic EPS | 27.04 | 27.81 | 27.40 | 27.05 | 26.28 |
| EPS Diluted | 39.29 | 38.29 | 40.41 | 37.76 | 33.85 |
| Normalized Diluted EPS | 25.44 | 26.06 | 25.61 | 25.35 | 24.64 |
| Average Basic Shares Outstanding | 430.50M | 431.60M | 430.60M | 428.80M | 427.70M |
| Average Diluted Shares Outstanding | 456.60M | 460.50M | 460.50M | 457.70M | 456.20M |
| Dividend Per Share | 0.88 | -- | -- | -- | -- |
| Payout Ratio | 2.08% | -- | -- | -- | -- |